CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Feature|Articles|October 8, 2026
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Advertisement
Advertisement
At ESC Congress 2026, incretin-based therapies, including GLP-1 receptor agonists, featured across heart failure (HF), chronic kidney disease (CKD), atrial fibrillation (AF), obesity and cardiovascular prevention, reflecting their continued evolution from metabolic drugs into broader cardiometabolic therapies.
Related to this article
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement